Adverse Events Reported with Therapies Targeting the CGRP Pathway During the First 6 Months Post-launch: A Retrospective Analysis Using the FDA Adverse Events Reporting System

INTRODUCTION: Through 2018, three calcitonin gene-related peptide pathway–targeted monoclonal antibodies (CGRP mAbs) had received US Food and Drug Administration (FDA) approval for migraine prevention: erenumab, fremanezumab, and galcanezumab. METHODS: This retrospective analysis evaluated adverse e...

Descripción completa

Detalles Bibliográficos
Autores principales: Silberstein, Stephen D., Reshef, Shoshana, Cohen, Joshua M., Gandhi, Sanjay, Seminerio, Michael, Ramirez Campos, Verena, Kessler, Yoel, Thompson, Stephen F., Blumenfeld, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898337/
https://www.ncbi.nlm.nih.gov/pubmed/36350532
http://dx.doi.org/10.1007/s12325-022-02346-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898337/
https://www.ncbi.nlm.nih.gov/pubmed/36350532
http://dx.doi.org/10.1007/s12325-022-02346-4

Ejemplares similares